7Baggers
 mizuho securities keeps their buy rating on corvus pharmaceuticals (crvs)  The Globe and Mail Wed, 12 Nov 2025 02:33:37 GMT
 Mizuho Securities Keeps Their Buy Rating on Corvus Pharmaceuticals (CRVS)  The Globe and Mail Tue, 11 Nov 2025 11:12:43 GMT
 Corvus Pharmaceuticals: Moving Slowly Forward (NASDAQ:CRVS)  Seeking Alpha Sun, 09 Nov 2025 15:46:02 GMT
 HC Wainwright Has Positive Outlook for CRVS FY2025 Earnings  Defense World Sat, 08 Nov 2025 08:03:01 GMT
 Real time social sentiment graph for Corvus Pharmaceuticals Inc.  newser.com Thu, 06 Nov 2025 06:01:45 GMT
 corvus pharmaceuticals reports positive q3 earnings call  TipRanks Thu, 06 Nov 2025 01:30:00 GMT
 corvus: q3 earnings snapshot  theheraldreview.com Wed, 05 Nov 2025 09:31:31 GMT
 Corvus Pharmaceuticals Reports Positive Q3 Earnings Call  TipRanks Wed, 05 Nov 2025 08:00:00 GMT
 corvus pharmaceuticals reports q3 eps (12c), consensus (12c)  TipRanks Tue, 04 Nov 2025 22:42:46 GMT
 Corvus: Q3 Earnings Snapshot  San Francisco Chronicle Tue, 04 Nov 2025 22:39:56 GMT
 Corvus Pharma Q3 net loss narrows; R&D expenses rise  MarketScreener Tue, 04 Nov 2025 08:00:00 GMT
 corvus to present final data on t cell lymphoma drug at ash meeting  Investing.com Nigeria Tue, 04 Nov 2025 03:06:22 GMT
 Corvus to present final data on T cell lymphoma drug at ASH meeting  Investing.com Mon, 03 Nov 2025 08:00:00 GMT

Corvus Pharmaceuticals, Inc
(NASDAQ:CRVS) 

CRVS stock logo

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is CPI-006, an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial that inhibits the production of aden...

Founded: 2014
Full Time Employees: 52
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends